Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Lam Research (LRCX, NASDAQ): To the Insiders -- Ignore unavailable to you. Want to Upgrade?

To: Cary Salsberg who wrote (4824)	8/27/2002 8:59:08 AM
From: Proud_Infidel	Respond to of 5867

ING Pilgrim Fund Manager: Lam Research Still Attractive 08/26 12:51 pm (DJ) Story 3116 (BSX, CMLS, LRCX, NOC) NEW YORK (Dow Jones)--Lam Research Corp. (LRCX) shares, despite being down more than 55% from their April 1 peak, remain an attractive investment, said Mary Lisanti, chief investment officer of equities with ING Pilgrim. Lam Research, Lisanti said, is in a cyclical industry - producing equipment used by semiconductor and flat-panel display makers - and its stock has suffered as investors have questioned the timing and strength of an economic recovery. She encourages investors to "buy cyclical stocks when people are nervous." Lisanti, who owns Lam Research shares, would use the recent slide as an "opportunity to buy more." Lam Research recently changed hands for $13.35, less than half its price on April 1. Lisanti likes Boston Scientific Corp. (BSX), noting that she expects the firm will be the No. 2 player in the drug-coated stent market. Boston Scientific's potential business of producing these stents, which help prop open clogged arteries, makes the stock worth more than the market currently has it priced. Boston Scientific shares recently traded for $29, just below the year high of $32.50 set June 20. Northrop Grumman Corp. (NOC), which builds technology for the defense industry, is also attractive, she said. As is radio-station operator Cumulus Media Inc. (CMLS), which is a "fabulous buy," Lisanti added. Northrop traded for $118.15 while Cumulus was at $14.85. -By Nick Baker, Dow Jones Newswires; 201 -938 -4047; nick.baker@dowjones.com (END) DOW JONES NEWS 08 -26 -02 12:51 PM